<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2021-25-6-39-48</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2048</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Влияние висцерального ожирения и адипокинового статуса на функциональное состояние почек у больных артериальной гипертензией, ожирением и хронической сердечной недостаточностью</article-title><trans-title-group xml:lang="en"><trans-title>Influence of viscersal obesity and adipokin status on the rsenal function in hyperstensive patients with obesity and chrsonic hearst failurse</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3306-0312</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стаценко</surname><given-names>М. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Statsenko</surname><given-names>M. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Проф. Стаценко Михаил Евгеньевич - доктор медицинских наук; проректор по научной работе, зав. кафедрой внутренних болезней.</p><p>Тел.: 8-(8442) 38-53-57; 53-23-35</p></bio><bio xml:lang="en"><p>Prof. Mikhail E. Statsenko - MD, PhD, DmedSci., Vice-rector for research, Head of the Department of Internal Medicine.</p><p>400131, Pavshih Bortscov sqr., 1, Volgograd, Volgograd, Phone: 8- (8442) 38-53-57; 5323-35</p></bio><email xlink:type="simple">mestatsenko@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6232-4583</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Деревянченко</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Derevyanchenko</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доц. Деревянченко Мария Владимировна - доктор медицинских наук.</p><p>Тел.: 89023866940</p></bio><bio xml:lang="en"><p>Dr. M. Derevyanchenko - MD, PhD, DmedSci., assistant of Professor, Department of Internal Medicine.</p><p>400001, Pugachevskaya str., app. 5G, flat 2, Volgograd, Phone: 89023866940</p></bio><email xlink:type="simple">derevjanchenko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5736-2235</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фабрицкая</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fabritskaya</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доц. Фабрицкая Светлана Валерьевна - кандидат медицинских наук; кафедра внутренних болезней.</p><p>Тел.: +79023104224</p></bio><bio xml:lang="en"><p>Svetlana V. Fabritskaya - Ph.D. of Medical Sciences. assistant of Professor, Department of Internal Medicine.</p><p>1, Pavshikh Bortsov Sq., Volgograd, 400131. Phone: +7(902)3104224</p></bio><email xlink:type="simple">lanabelenkova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9351-3002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рындина</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryndina</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аспирант Рындина Юлия Андреевна - кафедра внутренних болезней.</p><p>Тел.: +7(937)5500708</p></bio><bio xml:lang="en"><p>Yuliya A. Rindina - PhD student, Department of Internal Medicine.</p><p>1, Pavshikh Bortsov Sq., Volgograd, 400131. Phone: +7(937)5500708</p></bio><email xlink:type="simple">rindina91@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Волгоградский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Volgograd State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2021</year></pub-date><volume>25</volume><issue>6</issue><fpage>39</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Стаценко М.Е., Деревянченко М.В., Фабрицкая С.В., Рындина Ю.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Стаценко М.Е., Деревянченко М.В., Фабрицкая С.В., Рындина Ю.А.</copyright-holder><copyright-holder xml:lang="en">Statsenko M.E., Derevyanchenko M.V., Fabritskaya S.V., Ryndina Y.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2048">https://journal.nephrolog.ru/jour/article/view/2048</self-uri><abstract><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ: оценить влияние висцерального ожирения, адипокинового статуса на функциональное состояние почек у больных артериальной гипертензией (АГ), ожирением и хронической сердечной недостаточностью (ХСН).</p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. 383 больных АГ 45-70 лет были разделены на четыре группы: 1-я группа - лица с АГ без ожирения и ХСН, 2-я группа - АГ + ожирение без ХСН, 3-я группа - АГ + ожирение + ХСН, 4-я группа - АГ + ХСН без ожирения. Проводили клиническое обследование, оценивали показатели висцерального ожирения, адипокинового статуса, функционального состояния почек. Помимо описательной статистики, сравнения групп между собой и корреляционного анализа, использовали многофакторный регрессионный анализ с построением уравнений регрессии.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Выявлены статистически значимые различия между 1-й и 2-й, 1-й и 3-й, 2-й и 4-й, 3-й и 4-й группами не только по индексу массы тела (ИМТ) - 23,9 [22,4; 24,3] vs 32,8 [31,1; 36,3], 23,9 [22,4; 24,3] vs 33,6 [30,8; 35,6], 32,8 [31,1; 36,3] vs 24,1 [23,1;24.5], 33,6 [30,8; 35,6] vs 24,1 [23,1; 24,5] кг/м2 соответственно, но и по проценту висцерального жира (7,0 [6,0; 8,0] vs 14,0 [11,0; 16,0] vs 18,0 [14,3; 22,0] vs 8,0 [5,0; 10,0] % в 1-й, 2-й, 3-й и 4-й группах соответственно - p1-2, p1-3, p2-3, Р2-4, P3-4 менее 0,0001, p1-4 = 0,022. Уровень лептина сыворотки крови был достоверно ниже в 1-й группе в сравнении со 2-й, 3-й, 4-й, а также в 4-й группе в сравнении с 3-й (6,9 [6,6; 22,7] vs 64,8 [59,3; 70,3], 63,6 [42,0; 86,1], 58,7 [18,9; 73.5]             и 58,7 [18,9; 73,5] vs 63,6 [42,0; 86,1] нг/мл соответственно). Концентрация адипонектина сыворотки крови была статистически значимо выше в 1-й группе в сравнении со 2-, 3-й и в 4-й группе в сравнении с 3-й (36,6 [29,2; 44,1] vs 18,9 [17,1; 20,6] vs 26,9 [22,2; 32,2] и 36,8 [20,2; 62,8] vs 26,9 [22,2; 32,2] нг/мл соответственно). Индекс висцерального ожирения (VAI) составил 1,49 [1,24; 2,07] vs 2,58 [2,03; 3,37] vs 3,08 [2,59; 3,84] vs 2,36 [1,81; 3,13] у.е. в 1-, 2-, 3-, 4-й группах соответственно, p1-2= 0,0007, p1-4=0,0001, p2-3=0,017, p1-3 иp3-4 менее 0,00001. Отмечено достоверное снижение скорости клубочковой фильтрации (СКФ) в 3-й и 4-й группах в сравнении с 1-й группой (59,0 [53,0; 67,8] и 69,0 [62,0; 83,0] vs 75,0 [68,0; 96,0] мл/мин/1,73 м2 соответственно), а также в 3-й группе в сравнении со 2-й и 4-й (59,0 [53,0; 67,8] vs 71,0 [60,0; 86,5] и 69,0 [62,0; 83,0] мл/мин/1,73 м2 соответственно). Уровень альбуминурии нарастал по мере присоединения к АГ ожирения и/или ХСН (14,2 [3,7; 44,4] vs 36,9 [13,6; 118,2] vs 149,8 [92,2; 247,6] vs 72,0 [36,2; 104,7] мг/г в 1-, 2-, 3-й и 4-й группах соответственно, различия статистически значимы между 1-й и 2-й, 1-й и 3-й, 1-й и 4-й, 2-й и 3-й, 3-й и 4-й группами). Концентрация р2-микроглобулинов в моче была достоверно ниже в 1-й группе в сравнении с 3-й и 4-й (0,10 [0,05; 0,42] vs 0,25 [0,20; 0,31] vs 0,27 [0,19; 0,31] мкг/мл). Корреляционный анализ выявил особенности влияния висцерального ожирения, адипокинового статуса на функциональное состояние почек в каждой из изучаемых групп.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Исследование подтвердило негативное влияние висцерального ожирения, гипер-лептинемии и гипоадипонектинемии на прогрессирующее ухудшение функционального состояния почек у больных АГ по мере присоединения к ней ожирения и/или ХСН.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>THE AIM</title><p>THE AIM: to evaluate the effect of visceral obesity, adipokine status on the functional state of the kidneys in patients with arterial hypertension (AH), obesity, and chronic heart failure (CHF).</p></sec><sec><title>PATIENTS AND METHODS</title><p>PATIENTS AND METHODS. 383 AH patients aged 45-70 years were divided into four groups: group 1 - persons with AH without obesity and CHF, group 2 - AH + obesity without CHF, group 3 - AH + obesity + CHF, group 4 - AH + CHF without obesity. A clinical examination was carried out, the indicators of visceral obesity, adipokine status, and functional state of the kidneys were assessed. In addition to descriptive statistics, comparison of groups with each other, and correlation analysis, multivariate regression analysis was used with the construction of regression equations.</p></sec><sec><title>RESULTS</title><p>RESULTS. Revealed statistically significant differences between 1 and 2, 1 and 3, 2 and 4, 3 and 4 groups not only in body mass index (BMI) - 23.9 [22.4; 24.3] vs 32.8 [31.1; 36.3], 23.9 [22.4; 24.3] vs 33.6 [30.8; 35.6], 32.8 [31.1; 36.3] vs 24.1 [23.1; 24.5], 33.6 [30.8; 35.6] vs 24.1 [23.1; 24.5] kg / m2, respectively, but also by the percentage of visceral fat (7.0 [6.0; 8.0] vs 14.0 [11.0; 16.0] vs 18.0 [14.3; 22.0] vs 8.0 [5.0; 10.0] % in groups 1,2, 3 and 4, respectively - p1-2, p1-3, p2-3, p2-4, p3-4 less than 0,0001, p1-4 = 0.022. The level of leptin in blood serum was significantly lower in group 1 in comparison with 2, 3, 4, and in group 4 in comparison with 3 (6.9 [6.6; 22.7] vs 64.8 [59.3; 70.3], 63.6 [42.0; 86.1], 58.7 [18.9; 73.5] and 58.7 [18.9; 73, 5] vs 63.6 [42.0; 86.1] ng / ml, respectively) The serum adiponectin concentration was statistically significantly higher in group 1 compared with group 2, 3 and in group 4 compared with group 3 (36.6 [29.2; 44.1] vs 18.9 [17.1; 20.6] vs 26.9 [22.2; 32.2] and 36.8 [20.2; 62.8] vs 26,9 [22.2; 32.2] ng / ml, respectively) Visceral obesity index (VAI) was 1.49 [1.24; 2.07] vs 2.58 [2.03; 3.37] vs 3.08 [2.59; 3.84] vs 2.36 [1.81; 3.13] c.u. in groups 1,2, 3, 4, respectively, p1-2 = 0.0007, p1 -4 = 0.0001, p2-3 = 0.017, p1-3 and p3-4 less than 0.00001. There was a significant decrease in the glomerular filtration rate (GFR) in groups 3 and 4 in comparison with group 1 (59.0 [53.0; 67.8] and 69.0 [62.0; 83.0] vs 75.0 [68.0; 96.0] ml / min / 1.73 m2, respectively), as well as in group 3 in comparison with 2 and 4 (59.0 [53.0; 67.8] vs 71.0 [60.0; 86, 5] and 69.0 [62.0; 83.0] ml / min / 1.73 m2, respectively). The level of albuminuria increased with adherence to hypertension of obesity and / or CHF (14.2 [3.7; 44.4] vs 36.9 [13.6; 118.2] vs 149.8 [92.2; 247, 6] vs 72.0 [36.2; 104.7] mg / g in groups 1,2, 3 and 4, respectively, the differences are statistically significant between 1 and 2, 1 and 3, 1 and 4, 2 and 3, 3 and 4 groups). The concentration of p2-microglobulins in urine was significantly lower in group 1 compared with groups 3 and 4 (0.10 [0.05; 0.42] vs 0.25 [0.20; 0.31] vs 0.27 [0,19; 0.31] pg / ml). Correlation analysis revealed the peculiarities of the influence of visceral obesity, adipokine status on the functional state of the kidneys in each of the studied groups.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. The study confirmed the negative effect of visceral obesity, hyperleptinemia, and hypoadiponectinemia on the progressive deterioration of the renal function in hypertensive patients with adherence to obesity and/or CHF.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>функциональное состояние почек</kwd><kwd>адипокиновый статус</kwd><kwd>лептин</kwd><kwd>адипонектин</kwd><kwd>висцеральное ожирение</kwd><kwd>артериальная гипертензия</kwd><kwd>хроническая сердечная недостаточность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>renal function</kwd><kwd>adipokine status</kwd><kwd>leptin</kwd><kwd>adiponectin</kwd><kwd>visceral obesity</kwd><kwd>arterial hypertension</kwd><kwd>chronic heart failure</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Муромцева ГА, Концевая АВ, Константинов ВВ и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11</mixed-citation><mixed-citation xml:lang="en">Muromtseva GA, Kontsevaya AV, Konstantinov VV et al. The pRevalence of non-infectious diseases risk factor in Russian population in 2012-2013 year. The results of ECVD-RF. Cardiovascular Therapy and Prevention 2014;13(6):4-11. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Российское кардиологическое общество (РКО). Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083</mixed-citation><mixed-citation xml:lang="en">Russian Society of Cardiology (RC). 2020 Clinical practice guidelines for Chronic heaRt failure. Russian Journal of Cardiology 2020;25(11):4083. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова ИЕ, Жернакова ЮВ от имени экспертов. Диагностика и лечение артериальной гипертонии: Клинические рекомендации. Системные гипертензии 2019:16(1):6-31. doi: 10.26442/2075082X.2019.1.190179</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YuV on behalf of the expeRts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension 2019;16(1):6-31. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W et al. 2018 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur Heart J 2018;39(33):3021-3104. doi:10.1093/ eurheartj/ehy339</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W et al. 2018 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Eur Heart J 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Omboni S, Posokhov I, Parati G et al. Variable association of 24-h peripheral and central hemodynamics and stiffness with hypertension-mediated organ damage: the VASOTENS registry. Journal of Hypertension 2020;38(4):701-715. doi:10.1097/HJH.0000000000002312</mixed-citation><mixed-citation xml:lang="en">Omboni S, Posokhov I, Parati G et al. Variable association of 24-h peripheral and central hemodynamics and stiffness with hypertension-mediated organ damage: the VASOTENS registry. Journal of Hypertension 2020;38(4):701-715. doi:10.1097/HJH.0000000000002312</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hall ME, do Carmo JM, da Silva AA et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol renovasc Dis 2014;18(7):75-88. doi:10.2147/IJNrD.S39739</mixed-citation><mixed-citation xml:lang="en">Hall ME, do Carmo JM, da Silva AA et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol renovasc Dis 2014;18(7):75-88. doi:10.2147/IJNrD.S39739</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко МЕ, Деревянченко МВ, Шилина НН и др. Функциональное состояние почек у больных с сердечнососудистыми заболеваниями и ожирением. Нефрология 2016;20(5):43-49</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Derevyanchenko MV, Shilina NN et al. Renal function in patients with cardiovascular disease and obesity. Nephrology 2016;20(5):43-49. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко МЕ, Деревянченко МВ. Особенности структурно-функционального состояния почек и эндотелия у больных с артериальной гипертензией в сочетании с метаболическими нарушениями. Нефрология 2017:21(5):14—21. doi:10.24884/1561-6274-2017-21-5-5-18</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Derevyanchenko MV. Features of the structural and the functional state of kidneys and the function of endothelium in hypertensive patients with metabolic disturbances. Nephrology 2017;21(5):14-21. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко МЕ, Деревянченко МВ. Функциональное состояние почек и сердечно-сосудистый риск у больных с артериальной гипертензией и ожирением: роль лептина и ади-понектина. Нефрология 2018:22(5):51-57. doi:10.24884/1561-6274-2018-22-5-51-57</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Derevyanchenko MV. Renal function and cardiovascular risk in patients with arterial hypertension and obesity: the role of leptin and adiponektin. Nephrology 2018;22(5):51-57. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Недогода СВ, Барыкина ИН, Саласюк АС. Национальные клинические рекомендации по ожирению: концепция и перспективы. Вестник Волгоградского государственного медицинского университета 2017;1(61):134—140</mixed-citation><mixed-citation xml:lang="en">Nedogoda SV, Barykina IN, Salasyuk AS. National clinical recommendations for obesity: concept and perpectives. Vestnik of Volgograd State medical univerity 2017;1(61):134-140. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Marco C Amato, Carla Giordano, Maria Pitrone, Aldo Gal-luzzo. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011; 10:183. doi:10.1186/1476-511X-10-183</mixed-citation><mixed-citation xml:lang="en">Marco C Amato, Carla Giordano, Maria Pitrone, Aldo Gal-luzzo. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011; 10:183. doi:10.1186/1476-511X-10-183</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612. doi:10.7326/0003-4819-150-9-200905050-00006.</mixed-citation><mixed-citation xml:lang="en">Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612. doi:10.7326/0003-4819-150-9-200905050-00006.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал 2018:23(6):7-122. doi:10.15829/1560-4071-2018-6-7-122</mixed-citation><mixed-citation xml:lang="en">Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology 2018;(6):7-122. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российское кардиологическое общество, Ассоциация сердечнососудистых хирургов России. Российский кардиологический журнал 2020;25(11):4103. doi:10.15829/1560-4071-2020-4103</mixed-citation><mixed-citation xml:lang="en">2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology 2020;25(11):4103. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mona P Nasrallah, Fuad N Ziyadeh. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephro 2013;33(1):54-65. doi:10.1016/j.semnephrol.2012.12.005</mixed-citation><mixed-citation xml:lang="en">Mona P Nasrallah, Fuad N Ziyadeh. Overview of the physiology and pathophysiology of leptin with special emphasis on its role in the kidney. Semin Nephro 2013;33(1):54-65. doi:10.1016/j.semnephrol.2012.12.005</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Traver JG, Kamal FA, Robbins J et al. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res 2016;118(6):1021-1040. doi: 10.1161/CIrCrESAHA.115.306565</mixed-citation><mixed-citation xml:lang="en">Traver JG, Kamal FA, Robbins J et al. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res 2016;118(6):1021-1040. doi: 10.1161/CIrCrESAHA.115.306565</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Гриценко ОВ, Чумакова ГА, Шевляков ИВ, Трубина ЕВ. Механизмы развития сердечной недостаточности при ожирении. Российский кардиологический журнал 2018;23(5):81-86. doi:10.15829/1560-4071-2018-5-81-86</mixed-citation><mixed-citation xml:lang="en">Gritsenko OV, Chumakova GA, Shevlyakov IV, Trubina EV. The mechanisms of heart failure development in obesity. Russian Journal of Cardiology 2018;(5):81-86. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко МЕ, Фабрицкая СВ, Рындина ЮА. Роль ожирения в поражении почек у больных с хронической сердечной недостаточностью. Нефрология 2020;24(5):29-36. doi:10.36485/1561-6274-2020-24-5-29-36</mixed-citation><mixed-citation xml:lang="en">Statsenko ME, Fabritskaya SV, Ryndina YuA. The role of obesity in renal damage in patients with chronic heart failure. Nephrology 2020;24(5):29-36. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hui-Mei Chen, Yan Chen, Yi-De Zhang et al. Evaluation of metabolic risk marker in obesity-related glomerulopathy. J Ren Nutr2011;21(4):309-315. doi:10.1053/j.jrn.2010.06.019</mixed-citation><mixed-citation xml:lang="en">Hui-Mei Chen, Yan Chen, Yi-De Zhang et al. Evaluation of metabolic risk marker in obesity-related glomerulopathy. J Ren Nutr2011;21(4):309-315. doi:10.1053/j.jrn.2010.06.019</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">John E Hall, Jussara M. do Carmo, Alexandre A da Silva et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116(6):991-1006. doi:10.1161/CIrCrESAHA.116.305697</mixed-citation><mixed-citation xml:lang="en">John E Hall, Jussara M. do Carmo, Alexandre A da Silva et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res 2015;116(6):991-1006. doi:10.1161/CIrCrESAHA.116.305697</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015;36(23):1437-1444. doi:10.1093/eur-heartj/ehv010</mixed-citation><mixed-citation xml:lang="en">Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015;36(23):1437-1444. doi:10.1093/eur-heartj/ehv010</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schefold JC, Filippatos G, Hasenfuss G et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 2016;12(10):610-623. doi: 10.1038/nrneph.2016.113</mixed-citation><mixed-citation xml:lang="en">Schefold JC, Filippatos G, Hasenfuss G et al. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol 2016;12(10):610-623. doi: 10.1038/nrneph.2016.113</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Garofalo C, Borrelli S, Minutolo R et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91(5):1224-1235. doi: 10.1016/j.kint.2016.12.013</mixed-citation><mixed-citation xml:lang="en">Garofalo C, Borrelli S, Minutolo R et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017;91(5):1224-1235. doi: 10.1016/j.kint.2016.12.013</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Вялкова АА, Лебедева ЕН, Красиков СИ и др. Клиникопатогенетические аспекты повреждения почек при ожирении (обзор литературы). Нефрология 2014;3(18):24-33</mixed-citation><mixed-citation xml:lang="en">Vyalkova AA, Lebedeva EN, Krasikov SI et al. Clinical and paphogenical aspects of kidney damage in obesity (review). Nephrology 2014;18(3):24-33. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol 2013;33(1):14-22. doi: 10.1016/j.semnephrol.2012.12.006</mixed-citation><mixed-citation xml:lang="en">Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol 2013;33(1):14-22. doi: 10.1016/j.semnephrol.2012.12.006</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Садулаева ИА, Васюк ЮА, Трофименко ОС и др. Ожирение при метаболическом синдроме и почечная дисфункция. Терапевтический архив 2016;88(10):93-98. doi:10.17116/terarkh201688693-98</mixed-citation><mixed-citation xml:lang="en">Sadulaeva IA., Vasyuk YuA, Trofimenko OS. et al. Obesity in metabolic syndrome, as well as kidney dysfunction. Ter arh 2016;88(10):93-98. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">John A D’Elia, Bijan Roshan, Manish Maski, Larry A. Wein-rauch Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney. Int J Nephrol renovasc Dis 2009;2:39-49. doi: 10.2147/ijnrd.s7999</mixed-citation><mixed-citation xml:lang="en">John A D’Elia, Bijan Roshan, Manish Maski, Larry A. Wein-rauch Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney. Int J Nephrol renovasc Dis 2009;2:39-49. doi: 10.2147/ijnrd.s7999</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Вялкова АА, Лебедева ЕН, Афонина СН и др. Заболевания почек и ожирение: молекулярные взаимосвязи и новые подходы к диагностике (обзор литературы. Нефрология 2017;21(3):25-38. doi:10.24884/1561-6274-2017-3-25-38</mixed-citation><mixed-citation xml:lang="en">Vyalkova AA, Lebedeva EN, Afonina SN et al. Kidney diseases and obesity: molecular relationship and new approaches to diagnosis (literature review). Nephrology 2017;21(3):25-38. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Locatelli F, Pozzoni P, Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006;17(4)2:81-85. doi: 10.1681/ASN.2005121332</mixed-citation><mixed-citation xml:lang="en">Locatelli F, Pozzoni P, Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006;17(4)2:81-85. doi: 10.1681/ASN.2005121332</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая болезнь почек. Клинические рекомендации 2021. Ассоциация нефрологов 2021;1-233. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf</mixed-citation><mixed-citation xml:lang="en">Chronic kidney disease. Clinical recommendations 2021. Association of Nephrologists 2021;1-233. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Крячкова АА, Савельева СА, Галлямов МГ и др. Роль ожирения в поражении почек при метаболическом синдроме. Нефрология и диализ 2010;12(1):34—38</mixed-citation><mixed-citation xml:lang="en">Kryachkova AA, Savelyeva SA, Gallyamov MG et al. The role of obesity in renal injury in patients with metabolic syndrome. Nephrology and dialysis 2010;12(1):34-38. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jerzy Chudek, Marcin Adamczak, Teresa Nieszporek, Andrzej Wiecek. Adipose tissue as an endocrine organ - a nephrologist’s perpective. Contrib Nephro 2006;151:70-90. doi: 10.1159/000095320</mixed-citation><mixed-citation xml:lang="en">Jerzy Chudek, Marcin Adamczak, Teresa Nieszporek, Andrzej Wiecek. Adipose tissue as an endocrine organ - a nephrologist’s perpective. Contrib Nephro 2006;151:70-90. doi: 10.1159/000095320</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Caroline MW, van Stijn, Jason Kim et al. Adiponectin expression protects against angiotensin Il-mediated inflammation and accelerated atherosclerosis. PLoS One 2014;9(1):86-94. doi: 10.1371/journal.pone.0086404</mixed-citation><mixed-citation xml:lang="en">Caroline MW, van Stijn, Jason Kim et al. Adiponectin expression protects against angiotensin Il-mediated inflammation and accelerated atherosclerosis. PLoS One 2014;9(1):86-94. doi: 10.1371/journal.pone.0086404</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
